Home / Categories / By country / America / North America / USA / HCP - USA
Click to view full size image
Click here for details on how to download this file to your desktop.

Xarelto

Xarelto
rivaroxaban tablets

The #1 prescribed novel oral anticoagulant in the US

The patients they studied are the ones I see.

AMONG NOVEL ORAL ANTICOAGULANTS:

Most real-world experience: more than 2 million patients prescribed in the US.

Most safety data generated in clinical trials in patients studied with high risk of thrombotic events.

Most affordable: the lowest average out-of-pocket cost.

Not intended to be a comparison of safety or efficacy outcomes.

LEARN WHY XARELTO is leading the new generation
visit www.XARELTOhcp.com

Anticoagulation has come of age for healthcare professionals, like me, who prescribe XARELTO

SIX INDICATIONS STRONG

• To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled
• For the treatment of deep vein thrombosis (DVT)
• For the treatment of pulmonary embolism (PE)
For the reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE
• For the prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery
• For the prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery

Xarelto
rivaroxaban tablets

Janssen Pharmaceuticals, Inc.


Download this ad as separate pages in JPEG format.
Other ads from this campaign

Brand: Xarelto
Country/Market: USA, North America
Target: Healthcare Professional (HCP)
Tagline: Generation Xarelto
Size/duration: Three-page ad
Publication/Aired:
Medical Economics - April 10, 2015


See more Xarelto ads here
Rate this file (No vote yet)
File information
Download:Available for logged-in users with full-size access enabled.
Filename:Xarelto_MedicalEconomics-April102015_hcpUSA_3P.jpg
Keywords:fd57SORu , 55047 , Generation Xarelto Campaign , Three-page ad , healthcare category , hcpUSA , USA , Healthcare Professional (HCP) , Print ad , English , MedicalEconomicsApr1015 , The ones I see , Creative , inspiration , art direction , graphic design , copywriting , copy writing , creative intelligence , competitive intelligence , purple color , Black and white photography , looking at camera , studio shot , white background , type treatment , big type , copy-intense , wordy , Lots Balancing Copy , Transparent box overlay , transparency , layered , busy layout , confused layout , Caucasian , female , woman , adult , middle-aged , Healthcare Professional , Doctor , Physician , testimonial , case study , Fictitious patient , Fictitious patients , Labcoat , Whitecoat , Lab coat , White coat , Stethoscope , Xarelto , Xarelto brand , Rivaroxaban , Bayer , Janssen , Johnson and Johnson , Afib , Anticoagulant , Anticoagulants , Atrial Fibrillation , Bayer , Blood Clotting , deep vein thrombosis , DVT , factor Xa inhibitor , hip , Janssen Pharmaceutica , knee , Morpholines , non-valvular atrial fibrillation , oral anticoagulant , PE , prevention , prevention of venous thromboembolism , prophylaxis , pulmonary embolism , replacement surgery , stroke , Thiophenes , thrombosis
Filesize:21499 KiB
Date added:Apr 28, 2015
Dimensions:11033 x 5304 pixels
Displayed:129 times
URL:https://adpharm.net/displayimage.php?pid=55047
My Collection:Add to collection
About Subscriptions Contact us Twitter LinkedIn